Aastrom Biosciences Inc (ASTM)

3.10
0.01 0.18
NASDAQ : Health Care
Prev Close 3.11
Open 3.10
Day Low/High 3.10 / 3.14
52 Wk Low/High 2.55 / 5.39
Volume 6.30K
Avg Volume 211.70K
Exchange NASDAQ
Shares Outstanding 23.79M
Market Cap 65.77M
EPS -5.18
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Treatment With Aastrom's Ixmyelocel-T Shown To Reduce Incidence Of Major Adverse Cardiovascular Events In Patients With Ischemic Dilated Cardiomyopathy

Treatment With Aastrom's Ixmyelocel-T Shown To Reduce Incidence Of Major Adverse Cardiovascular Events In Patients With Ischemic Dilated Cardiomyopathy

Results From Phase 2a IMPACT-DCM and Catheter-DCM Studies Published in Circulation Research

Aastrom Announces Appointment Of Zac Taylor As National Sales Director

Aastrom Announces Appointment Of Zac Taylor As National Sales Director

Experienced Senior Sales Professional Brings Wealth of Marketing, Strategic Planning and Brand Management Expertise to Aastrom

Aastrom Announces Appointment Of Gerard Michel As Chief Financial Officer And Vice President, Corporate Development

Aastrom Announces Appointment Of Gerard Michel As Chief Financial Officer And Vice President, Corporate Development

Accomplished Industry Veteran Brings Extensive History of Successful Corporate Development, Fundraising and Capital Management to Aastrom

Aastrom Biosciences Reports First-Quarter 2014 Financial Results

Aastrom Biosciences Reports First-Quarter 2014 Financial Results

Conference Call May 15, 2014 at 4:30 PM Eastern Time

Why Aastrom Biosciences (ASTM) Stock Is Soaring Today

Why Aastrom Biosciences (ASTM) Stock Is Soaring Today

Aastrom Biosciences (ASTM) soared Monday after the company announced its acquisition of Sanofi's Cell Therapy and Regenerative Medicine, or CTRM, business for $6.5 million. Aastrom will pay $4 million in cash and $2.5 million in a promissory note for the business. The company expects the acquisition to close in approximately three weeks. The acquisition gives Aastrom global commercial rights to three marketed autologous cell therapy products called Carticel, Epicel and MACI. Revenues of those three products totaled $44 million in 2013. Aastrom will also acquire manufacturing and production centers in the U.S. and Denmark. The stock was up 32.1% to $46.5 at 11:15 a.m., by which point it had eclipsed its average volume of 380,200 with more than 1.6 million shares traded for the day. Aastrom hit a high of $4.95 for the day as of that time.

Aastrom Announces Definitive Agreement To Acquire Sanofi's Cell Therapy And Regenerative Medicine Business

Aastrom Announces Definitive Agreement To Acquire Sanofi's Cell Therapy And Regenerative Medicine Business

Acquisition of Landmark Autologous Cell Therapy Portfolio and Manufacturing Centers in U.S. and Europe Positions Aastrom as a Global Leader in Regenerative Medicine

Aastrom Announces Appointments Of Dr. Ross Tubo As Chief Scientific Officer And Dr. David Recker As Chief Medical Officer

Aastrom Announces Appointments Of Dr. Ross Tubo As Chief Scientific Officer And Dr. David Recker As Chief Medical Officer

Globally Recognized Industry Veterans Bring Extensive R&D and Product Development Experience in Regenerative Medicine and Multiple Therapeutic Areas

Rev Shark: Market Chaos Theory

Rev Shark: Market Chaos Theory

Peculiar rotations and odd selloffs capped a chaotic market week.

Aastrom Biosciences Reports Fourth-Quarter And Year-End 2013 Financial Results

Aastrom Biosciences Reports Fourth-Quarter And Year-End 2013 Financial Results

Conference Call March 13, 2014 at 4:30 PM Eastern Time

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.